Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

Employer-sponsored cancer benefits should be designed around the specific needs of a workforce rather than generic access ...

Differences in the memory B-cell compartment were measurable on the day antiviral therapy stopped, separating the patients with chronic hepatitis B who would go on to clear surfac ...

Dosing also diverged from the approved label. Regorafenib's standard dose (RSD) is an average daily dose of 160 mg for 21 days of a 28-day cycle, yet more than a quarter of patients (26.5%) were ...

However, the risk of these rare cancers is not enough to dissuade prescribing CAR T-cell therapy for CLL, explains Kerry Rogers, MD, The James.

Bundled payment models offer employers and community oncology practices greater cost predictability while improving patient access, Baird said.

Even with MINT's mandatory steroid taper, inebilizumab still cut exacerbation and rescue therapy rates versus placebo, said ...

Experts at ERS Congress 2026 discuss why attending respiratory conferences drives learning, networking, and better patient ...

Terminology shifts to “decompensated heart failure,” introducing an initial–stabilization–pre/postdischarge framework and ...

Employers can advance innovative cancer care by tailoring benefits and support to their workforce's needs, according to Rosa Novo, executive benefits director at Miami-Dade County Public Schools ...

Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting ...

Keith Kaye, MD, MPH, explains how shorter antibiotic courses and optimized dosing help balance treatment efficacy against C.